1stOncology™: Cancer Intelligence Service – Page 14371 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Varian to Present at the Citi Global Healthcare Conference

On November 19, 2018 Varian (NYSE: VAR) reported that Gary Bischoping, chief financial officer, will present at the Citi Global Healthcare Conference in New York City, scheduled for 11:00 a.m. Eastern Time on December 5, 2018 (Press release, Varian Medical Systems, NOV 19, 2018, View Source [SID1234531442]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Information about the webcast of the company’s presentation will be available through a link on the company website at www.varian.com/investors.

vTv Therapeutics to Present at the 30th Annual Piper Jaffray Healthcare Conference

On November 19, 2018 vTv Therapeutics Inc. (Nasdaq: VTVT) reported that company management will present a corporate overview at the Piper Jaffray 30th Annual Healthcare Conference on Tuesday, Nov. 27, 2018 at 2:10 p.m. ET in New York City (Press release, vTv Therapeutics, NOV 19, 2018, View Source;p=irol-newsArticle&ID=2377689 [SID1234531441]).

A live webcast of the presentation can be accessed here and will be archived for 30 days following the presentation at www.vtvtherapeutics.com.

vTv Therapeutics is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. vTv has a pipeline of clinical drug candidates led by programs for the treatment of Alzheimer’s disease and diabetes as well as treatment of inflammatory disorders.

TRACON Pharmaceuticals Presents Data From Phase 2 Trial Of TRC102 And Temodar® In Patients With Recurrent Glioblastoma At Society For Neuro-Oncology Annual Meeting

On November 19, 2018 TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, reported its data from the Company’s Phase 2 study of TRC102 and Temodar (temozolomide) in patients with recurrent glioblastoma at the Society for Neuro-Oncology (SNO) annual meeting, taking place in New Orleans (Press release, Tracon Pharmaceuticals, NOV 19, 2018, View Source [SID1234531440]). TRC102 is a small molecule inhibitor of the base excision repair (BER) pathway that causes resistance to Temodar chemotherapy in preclinical tumor models.

In an oral presentation by Dr. Lisa Rogers, Director of Medical Neuro-Oncology at Cleveland Medical Center, entitled, "Phase 2 Trial of Temozolomide and TRC102, Base Excision Repair Inhibitor, in Bevacizumab Naive Glioblastoma at First Recurrence", safety and efficacy data were presented from patients who received TRC102 and Temodar at the time of recurrence following first line therapy with Temodar chemotherapy and radiation therapy.

The combination of TRC102 and Temodar was tolerable, but did not meet the primary efficacy endpoint of demonstrating objective responses by Response Assessment in Neuro-Oncology criteria in the initial 19 enrolled patients, most of whom were treated at Cleveland Clinic. Two patients (10.5%) demonstrated evidence of clinical benefit and met the secondary endpoint of progression free survival (PFS) beyond 6 months. Both patients who demonstrated PFS for more than 11 months remain alive over 30 months following treatment initiation with TRC102 and Temodar for recurrent glioblastoma. PFS of greater than 11 months was associated with N-methylpurine DNA glycosylase expression, a biomarker that initiates the BER pathway of resistance that is inhibited by TRC102.

"We recognized that the primary endpoint of objective response in the Phase 2 trial of Temodar and TRC102 represented a high efficacy hurdle, that of resensitizing recurrent glioblastoma patients to Temodar treatment. We were encouraged to see certain patients demonstrate prolonged clinical benefit that was associated with evidence of activation of the BER pathway of resistance that is inhibited by TRC102," said Dr. Charles Theuer, President and CEO of TRACON Pharmaceuticals. "Our efforts will continue to focus on identifying possible biomarkers that are prognostic of response to TRC102 in four ongoing clinical trials supported by the National Cancer Institute."

About TRC102

TRC102 is a novel, clinical stage small molecule inhibitor of the base excision repair pathway that is implicated in resistance to alkylating and antimetabolite chemotherapy. TRC102 has been combined safely with Temodar, Alimta (pemetrexed) and Fludara (fludarabine) in phase 1 trials and is being studied in a broad program of clinical trials supported by the National Cancer Institute, including a Phase 2 trial of TRC102 and Temodar in patients with solid tumors, a Phase 2 trial of TRC102 and Alimta in patients with non-small cell lung cancer, a Phase 1 trial of TRC102 with chemotherapy and radiation therapy in patients with non-small cell lung cancer, and a Phase 1 trial of TRC102 with Alimta and cisplatin in patients with solid tumors. For more information about the clinical trials, please visit TRACON’s website at www.traconpharma.com/clinical_trials.php.

Actinium Pharmaceuticals, Inc. to Present at 30th Annual Piper Jaffray Healthcare Conference

On November 19, 2018 Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) reported that management will present at the 30th Annual Piper Jaffray Healthcare conference that is being held at the Lotte New York Palace hotel, November 26-29 (Press release, Actinium Pharmaceuticals, NOV 19, 2018, View Source [SID1234531439]). The live webcast of the presentation will be available on Actinium’s investor relations webpage at: View Source or by clicking on the following link: View Source;tp_key=f710d7f814. Details of Actinium’s presentation are as follows:

Date: Tuesday, November 27, 2018
Time: 2:10 PM ET
Location: Harlem Track – Kennedy 2, 4th Floor
Venue: Lotte New York Palace

Conference attendees may schedule a meeting with Actinium’s management by contacting Steve O’Loughlin, Actinium’s Principal Financial Officer, [email protected].

Genomic Health Announces Presentation of Two Large Studies at the 2018 San Antonio Breast Cancer Symposium, Reinforcing Real-world Value of the Oncotype DX Breast Recurrence Score® Test

On November 19, 2018 Genomic Health, Inc. (NASDAQ: GHDX) reported that it will present results from two large studies of the Oncotype DX Breast Recurrence Score test at the 2018 San Antonio Breast Cancer Symposium (SABCS), which will be held December 4-8 (Press release, Genomic Health, NOV 19, 2018, View Source [SID1234531438]). The study findings reinforce the value of the Oncotype DX test in optimizing treatment and outcomes in patients with both node-negative and node-positive early-stage breast cancer. Presentations include:

Results from a large population-based clinical outcomes study based on the Surveillance, Epidemiology, and End Results (SEER) registry program of the National Cancer Institute (NCI), the premier source of cancer statistics in the United States. To provide long-term (nine years) real-world evidence for both prognosis and chemotherapy benefit, the study assessed breast cancer-specific survival in patients with node-negative and node-positive disease who were treated based on their Oncotype DX Breast Recurrence Score test results.
Analysis of 500 early-stage breast cancer patients age 40 or younger to further the understanding of the value of the Oncotype DX test in guiding chemotherapy treatment decisions. The analysis is based on a multi-center prospective cohort study led by Dana-Farber Cancer Institute investigators in Boston.
Complete results from both studies will be announced in accordance with the SABCS embargo policy. Following are details for the two poster presentations:

Abstract: P3-11-02Poster: Breast cancer specific mortality in patients with node-negative and node-positive breast cancer guided by the 21-gene assay: A SEER-genomic population-based studyAuthors: Hortobagyi GN, Shak S, Sledge GW Jr., Winer EP, Albain KS, Mamounas EP, Jakubowski DM, Petkov VI, Wolmark NLocation: Hall 1Date and Time: Thursday, December 6, 7-9 a.m. CST
Abstract: P2-08-07Poster: Prognostic impact of the 21-gene Recurrence Score assay among young women with node-negative and node-positive early-stage breast cancerAuthors: Poorvu PD, Gelber SI, Rosenberg SM, Ruddy KJ, Tamimi RM, Collins LC, Peppercorn J, Schapira L, Borges VF, Come SE, Warner E, Jakubowski DM, Russell C, Winer EP, Partridge AHLocation: Hall 1Date and Time: Thursday, December 6, 7-9 a.m. CST
About Oncotype DX
The Oncotype DX portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumor in order to optimize cancer treatment decisions. The company’s flagship product, the Oncotype DX breast cancer test, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer. Additionally, the test predicts the likelihood of recurrence in a pre-invasive form of breast cancer called DCIS. With more than 950,000 patients tested in more than 90 countries, the Oncotype DX tests have redefined personalized medicine by making genomics a critical part of cancer diagnosis and treatment. To learn more about Oncotype DX tests, visit www.OncotypeDX.com or www.MyBreastCancerTreatment.org.